Class 4 Medicines Defect Notification: Baxter Healthcare Corporation, Onkotrone Injection 2 mg/ml concentrate for solution for infusion, EL(26)A/14
Authored by Medicines and Healthcare products Regulatory Agency (MHRA)Originally published 17 Mar 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Audio Version
- Add to preferred sources on Google
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Baxter Healthcare Corporation have informed the MHRA that the Patient Information Leaflet (PIL) packed in specified batches does not contain up to date information relating to the duration of contraception required for femal…
Read the full update from MHRA
About MHRA alerts and recalls
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare system. When new safety concerns are identified, or when issues arise with the manufacture or distribution of a medicine or device, the MHRA issues alerts and recalls to protect patients and support healthcare professionals.
These alerts can take several forms. Some provide updated guidance on prescribing or monitoring requirements for medicines and vaccines. Others may highlight newly recognised side effects, or remind clinicians of important risk-mitigation steps. In the case of medical devices, alerts may cover field safety notices, product recalls, or urgent device modifications. All of these communications are designed to ensure that products are used safely and that any risks are managed appropriately.
Patient.info republishes MHRA alerts and recalls so that this information is available quickly and accessibly to both healthcare professionals and the public. The summary above is taken directly from the MHRA’s official publication. To read the full advice, including detailed recommendations for prescribers, manufacturers and patients, please follow the “Read more” link to the MHRA website.
If you are a healthcare professional, you should consult the full notice to confirm the latest prescribing information, monitoring requirements and any actions you need to take in your practice. If you are a patient or carer, do not stop treatment or make changes to your medication or device without first seeking professional advice. If you have any concerns about your medicine or device, speak to your GP, pharmacist or specialist nurse.
Contains public sector information licensed under the Open Government Licence v3.0.
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
About the authorView full bio

Medicines and Healthcare products Regulatory Agency (MHRA)
UK Government Agency
Article history
The information on this page is written and peer reviewed by qualified clinicians.
Article also available in English, German, Spanish, French, Italian, Portuguese, Hindi, Hebrew, Arabic, and Swedish.
17 Mar 2026 | Originally published
Authored by:
Medicines and Healthcare products Regulatory Agency (MHRA)

Ask, share, connect.
Browse discussions, ask questions, and share experiences across hundreds of health topics.

Feeling unwell?
Assess your symptoms online for free
More in alerts, recalls and safety information
- Allurion Gastric Balloon: Updated safety information due to the risks of gastric outlet obstruction, small bowel obstruction and gastric perforation (DSI/2026/004)
- BD BodyComm™ version 3.3 software used for BodyGuard infusion pumps, BodyGuard-T and T34 syringe drivers: Important steps to manage transition to Windows 11 (DSI/2025/006)
- Class 2 Medicines Recall: Baxter Healthcare Limited, Compound Sodium Lactate Solution for Infusion BP (Hartmann's Solution for infusion) in Viaflo 1000ml, EL(25)A/46
- NewClass 2 Medicines Recall: Bristol Laboratories Limited, Phenoxymethylpenicillin 250 mg/5ml Sugar free Oral Solution BP, EL(26)A/33
- Class 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07
- Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Limited, Fingolimod Glenmark 0.5 mg Hard Capsules, EL(26)A/02
- Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Atorvastatin 20mg and 80mg Film-coated Tablets, EL(25)A/48
- Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film, EL(25)A/47
- Class 4 Medicines Defect Notification: Sandoz Limited, Apixaban 2.5mg and 5mg Tablets, EL(26)A/17
- Field Safety Notices: 02-06 February 2026
- Field Safety Notices: 1 May 2026
- NewField Safety Notices: 15 to 19 June 2026
- NewField Safety Notices: 22 to 26 May 2026
- Field Safety Notices: 22-26 December 2025
- Field Safety Notices: 23-27 February 2026
- Field Safety Notices: 29 September to 3 October 2025
- IXCHIQ Chikungunya vaccine: updates to restrictions of use following safety review
- MHRA Safety Roundup: April 2026
- Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
- Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)